1. Home
  2. ARDX vs UPBD Comparison

ARDX vs UPBD Comparison

Compare ARDX & UPBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARDX
  • UPBD
  • Stock Information
  • Founded
  • ARDX 2007
  • UPBD 1986
  • Country
  • ARDX United States
  • UPBD United States
  • Employees
  • ARDX N/A
  • UPBD N/A
  • Industry
  • ARDX Biotechnology: Pharmaceutical Preparations
  • UPBD Diversified Commercial Services
  • Sector
  • ARDX Health Care
  • UPBD Consumer Discretionary
  • Exchange
  • ARDX Nasdaq
  • UPBD Nasdaq
  • Market Cap
  • ARDX 1.3B
  • UPBD 1.2B
  • IPO Year
  • ARDX 2014
  • UPBD 1995
  • Fundamental
  • Price
  • ARDX $3.39
  • UPBD $24.84
  • Analyst Decision
  • ARDX Strong Buy
  • UPBD Buy
  • Analyst Count
  • ARDX 8
  • UPBD 5
  • Target Price
  • ARDX $10.19
  • UPBD $36.60
  • AVG Volume (30 Days)
  • ARDX 6.4M
  • UPBD 564.4K
  • Earning Date
  • ARDX 05-01-2025
  • UPBD 05-01-2025
  • Dividend Yield
  • ARDX N/A
  • UPBD 6.21%
  • EPS Growth
  • ARDX N/A
  • UPBD N/A
  • EPS
  • ARDX N/A
  • UPBD 2.13
  • Revenue
  • ARDX $361,706,000.00
  • UPBD $4,400,960,000.00
  • Revenue This Year
  • ARDX $15.74
  • UPBD $8.37
  • Revenue Next Year
  • ARDX $34.56
  • UPBD $6.79
  • P/E Ratio
  • ARDX N/A
  • UPBD $11.94
  • Revenue Growth
  • ARDX 127.33
  • UPBD 8.07
  • 52 Week Low
  • ARDX $3.62
  • UPBD $19.68
  • 52 Week High
  • ARDX $9.20
  • UPBD $38.72
  • Technical
  • Relative Strength Index (RSI)
  • ARDX 28.22
  • UPBD 58.67
  • Support Level
  • ARDX $3.50
  • UPBD $22.99
  • Resistance Level
  • ARDX $3.72
  • UPBD $26.76
  • Average True Range (ATR)
  • ARDX 0.26
  • UPBD 0.91
  • MACD
  • ARDX -0.13
  • UPBD 0.43
  • Stochastic Oscillator
  • ARDX 0.63
  • UPBD 72.14

About ARDX Ardelyx Inc.

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

Share on Social Networks: